Tests BS01, a light-sensitive gene treatment, in people with retinitis pigmentosa
Tests BS01 in adults with retinitis pigmentosa, an inherited eye disease.
Plain-language title generated from the registry record
Registry title: BS01 in Patients With Retinitis Pigmentosa
Key facts
- Where
- Teaneck, United StatesSee the site
- Phase
- Phase 1/2
Where in United States
- New Jersey RetinaTeaneck, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Bionic Sight LLC
- Trial code
- NCT04278131
- Record updated
- 23 January 2026
- Original description
A Phase 1/2, Safety and Efficacy Trial of BS01, a Recombinant Adeno-Associated Virus Vector Expressing ChronosFP (AAV2-CAG-ChronosFP) in Patients with Retinitis PigmentosaRead full original descriptionShow less
Phase 1/2, Safety and Efficacy Trial of BS01, a Recombinant Adeno-Associated Virus Vector Expressing ChronosFP in Patients With Retinitis Pigmentosa
A Phase 1/2, Safety and Efficacy Trial of BS01, a Recombinant Adeno-Associated Virus Vector Expressing ChronosFP (AAV2-CAG-ChronosFP) in Patients with Retinitis Pigmentosa
Inclusion: Confirmed diagnosis of retinitis pigmentosa; At least one eye with vision no better than 20/160 visual acuity on the EDTRS scale or, for patients with peripheral vision loss, a visual field no greater than 30°.
Exclusion: Prior receipt of any AAV gene therapy product; Large amplitude nystagmus.